Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.
9 Citations
323 Claims
-
1-203. -203. (canceled)
-
204. A method comprising the steps of:
-
(a) choosing on or more EPO dosage regimens, wherein said one or more EPO dosage regimens maintains at least a serum EPO concentration above a predose level for about 5 to 30 days;
(b) using a pharmacokinetic/pharmacodynamic model to determine the pharmacodynamic profile of said one or more EPO dosage regimens; and
(c) selecting said one or more EPO dosage regimens that provide said desired pharmacodynamic response based on said pharmacodynamic profile. - View Dependent Claims (205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 323)
-
-
234. A method comprising the steps of:
-
a) selecting one or more desired pharmacodynamic responses;
b) using a pharmacokinetic/pharmacodynamic model to determine EPO dosage regimens that provides said desired one or more pharmacodynamic responses; and
c) selecting the one or more EPO dosage regimens that provide said desired pharmacodynamic responses, wherein said one or more EPO dosage regimens maintains at least a serum EPO concentration above a predose level for about 5 to about 30 days. - View Dependent Claims (235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263)
-
-
264. A method comprising the steps of:
-
a) choosing on or more EPO dosage regimens, wherein said one or more EPO dosage regimens maintains at least a serum EPO concentration above a predose level for about 5 to 30 days;
b) using a pharmacokinetic/pharmacodynamic model to determine the pharmacokinetic profile of said one or more EPO dosage regimens; and
c) selecting said one or more EPO dosage regimens that provide said desired pharmacokinetic response based on said pharmacokinetic profile. - View Dependent Claims (265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293)
-
-
294. A method comprising the steps of
a) selecting one or more desired pharmacokinetic responses; -
b) using a pharmacokinetic/pharmacodynamic model to determine EPO dosage regimens that provide said desired one or more pharmacokinetic responses, and c) selecting one or more EPO dosage regimens that provide said desired pharmacokinetic responses, wherein said one or more EPO dosage regimens maintains at least a serum EPO concentration above a predose level for about 5 to 30 days. - View Dependent Claims (295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322)
-
Specification